Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))

311 Study Group

doi:10.1016/j.kint.2021.03.008

Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))

311 Study Group

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors regret that 2 investigators were not included in the 311 Study Group. Members of the 311 Study Group are listed in the Appendix. The authors would like to apologize for any inconvenience caused.

Original language	English
Pages (from-to)	1244
Number of pages	1
Journal	Kidney International
Volume	99
Issue number	5
DOIs	https://doi.org/10.1016/j.kint.2021.03.008
Publication status	Published - 2021 May

Bibliographical note

Publisher Copyright:
© 2021 International Society of Nephrology

All Science Journal Classification (ASJC) codes

Nephrology

Access to Document

10.1016/j.kint.2021.03.008

Fingerprint

Dive into the research topics of 'Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))'. Together they form a unique fingerprint.

Cite this

311 Study Group (2021). Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)). Kidney International, 99(5), 1244. https://doi.org/10.1016/j.kint.2021.03.008

311 Study Group. / Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)). In: Kidney International. 2021 ; Vol. 99, No. 5. pp. 1244.

@article{4f2d809138ee4696bf954a1d9b36fa5e,

title = "Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na{\"i}ve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))",

abstract = "The authors regret that 2 investigators were not included in the 311 Study Group. Members of the 311 Study Group are listed in the Appendix. The authors would like to apologize for any inconvenience caused.",

author = "{311 Study Group} and Eric Rondeau and Marie Scully and Gema Ariceta and Tom Barbour and Spero Cataland and Nils Heyne and Yoshitaka Miyakawa and Stephan Ortiz and Eugene Swenson and Marc Vallee and Yoon, {Sung Soo} and David Kavanagh and Hermann Haller and Sunil Babu and Nilufer Broeders and Nicole Lietar and Fiona Brown and Philip Campbell and Campistol, {Josep M.} and Miquel Blasco and Paramit Chowdhury and Theo Kasimatis and Lino Cirami and Leonardo Caroti and Guilia Antognoli and Yahsou Delmas and Vladimir Dobronravov and Anja Gaeckler and Cyril Garrouste and Gregory Greenwood and Si{\^a}n Griffin and Huang, {Chiu Ching} and Chen, {I. Ru} and Susan Huang and Kim, {Jin Seok} and {La Manna}, Gaetano and Giorgia Comai and Maria Cappuccilli and {Le Quintrec}, Moglie and Guillaume Jeantet and Iino Fumie and Yosu Luque and Jan Menne and Johan Morelle and Eric Goffin and Anja Muhlfeld and Shashi Nagaraj and Gowthami Arepally and Doyeun Oh and Masayoshi Okumi",

note = "Publisher Copyright: {\textcopyright} 2021 International Society of Nephrology",

year = "2021",

month = may,

doi = "10.1016/j.kint.2021.03.008",

language = "English",

volume = "99",

pages = "1244",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "5",

}

311 Study Group 2021, 'Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))', Kidney International, vol. 99, no. 5, pp. 1244. https://doi.org/10.1016/j.kint.2021.03.008

Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)). / 311 Study Group.

In: Kidney International, Vol. 99, No. 5, 05.2021, p. 1244.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))

AU - 311 Study Group

AU - Rondeau, Eric

AU - Scully, Marie

AU - Ariceta, Gema

AU - Barbour, Tom

AU - Cataland, Spero

AU - Heyne, Nils

AU - Miyakawa, Yoshitaka

AU - Ortiz, Stephan

AU - Swenson, Eugene

AU - Vallee, Marc

AU - Yoon, Sung Soo

AU - Kavanagh, David

AU - Haller, Hermann

AU - Babu, Sunil

AU - Broeders, Nilufer

AU - Lietar, Nicole

AU - Brown, Fiona

AU - Campbell, Philip

AU - Campistol, Josep M.

AU - Blasco, Miquel

AU - Chowdhury, Paramit

AU - Kasimatis, Theo

AU - Cirami, Lino

AU - Caroti, Leonardo

AU - Antognoli, Guilia

AU - Delmas, Yahsou

AU - Dobronravov, Vladimir

AU - Gaeckler, Anja

AU - Garrouste, Cyril

AU - Greenwood, Gregory

AU - Griffin, Siân

AU - Huang, Chiu Ching

AU - Chen, I. Ru

AU - Huang, Susan

AU - Kim, Jin Seok

AU - La Manna, Gaetano

AU - Comai, Giorgia

AU - Cappuccilli, Maria

AU - Le Quintrec, Moglie

AU - Jeantet, Guillaume

AU - Fumie, Iino

AU - Luque, Yosu

AU - Menne, Jan

AU - Morelle, Johan

AU - Goffin, Eric

AU - Muhlfeld, Anja

AU - Nagaraj, Shashi

AU - Arepally, Gowthami

AU - Oh, Doyeun

AU - Okumi, Masayoshi

PY - 2021/5

Y1 - 2021/5

N2 - The authors regret that 2 investigators were not included in the 311 Study Group. Members of the 311 Study Group are listed in the Appendix. The authors would like to apologize for any inconvenience caused.

AB - The authors regret that 2 investigators were not included in the 311 Study Group. Members of the 311 Study Group are listed in the Appendix. The authors would like to apologize for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85103752246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103752246&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2021.03.008

DO - 10.1016/j.kint.2021.03.008

M3 - Comment/debate

C2 - 33892867

AN - SCOPUS:85103752246

SN - 0085-2538

VL - 99

SP - 1244

JO - Kidney International

JF - Kidney International

IS - 5

ER -

311 Study Group. Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)). Kidney International. 2021 May;99(5):1244. doi: 10.1016/j.kint.2021.03.008